At a Glance
- Company: Novo Nordisk
- Partner: OpenAI
- Location: Denmark/global
- Focus area: AI across R&D, manufacturing and commercial functions
- Next steps: Full integration targeted by end-2026
What happened?
Novo Nordisk has entered a major collaboration with OpenAI to integrate artificial intelligence across its global operations. The rollout is intended to support drug discovery, research and development, manufacturing and commercial work, with full integration targeted for the end of 2026.
Why does it matter?
The deal signals how large drugmakers are trying to use generative AI and machine learning to speed up hypothesis testing, analyse larger datasets and shorten development timelines. For a company like Novo Nordisk, which is under pressure to sustain its leadership in obesity and diabetes drugs, faster decision-making across the pipeline could translate into a competitive edge.
Who’s behind it?
Novo Nordisk is one of the world’s biggest diabetes and obesity drugmakers, and OpenAI is the artificial intelligence company behind ChatGPT and related enterprise AI tools. The collaboration appears aimed at embedding AI into day-to-day scientific and business workflows rather than limiting it to one research project.
How was it achieved?
According to the announcement, the companies plan to connect AI systems to large internal datasets so teams can test ideas more quickly and support decisions across functions. The focus is on broad operational integration, including discovery science, manufacturing processes and commercial planning, rather than a single product-level application.
What’s next?
The main milestone is full integration by the end of 2026. If the rollout goes as planned, Novo Nordisk could use AI more systematically to support pipeline prioritisation, process optimisation and market-facing decisions across its organisation.